laddawan punna/iStock via Getty Images Arcutis Biotherapeutics Overview The last time I spoke about Arcutis Biotherapeutics, Inc. ( NASDAQ: ARQT ) it was gearing up to expand the label of its drug Zoryve [roflumilast] in several ways. I'm pleased to say that since then, it has attained most of this goal.
Firstly, it had already received approval of this drug for the treatment of plaque psoriasis patients ages 12 and older, as stated in my prior article. The article was entitled " Arcutis Biotherapeutics: PDUFA Date Before End Of 2023 Makes This Worth A Look. " However, it was able to expand the label of Zoryve for the plaque psoriasis indication even further.
This was with the ability to target younger patients, ages 6 to 11. Regarding the seborrheic dermatitis indication, Zoryve foam was approved by the FDA to treat this patient population. One of the label expansions I noted has not yet been attained, but this sets up a major catalyst opportunity for investors to look forward to.
There is a PDUFA date established for July 7th, 2024, by which the FDA will decide whether Zoryve should be approved to treat patients with atopic dermatitis. Lastly, regardless of the outcome of this decision, sales of Zoyrve have grown substantially. Matter of fact, Q1 2024 earnings just released showed that sales of the drug grew by 675% to $21.
6 million. If such a growth trend continues, then I believe this could become a good long-term name to hold on to. A Few Label Expansions Achieved Should.